Edition:
India

Eleven Biotherapeutics Inc (EBIO.OQ)

EBIO.OQ on NASDAQ Stock Exchange Global Market

0.65USD
12:59am IST
Change (% chg)

$-0.03 (-3.89%)
Prev Close
$0.68
Open
$0.70
Day's High
$0.70
Day's Low
$0.65
Volume
135,869
Avg. Vol
71,979
52-wk High
$2.71
52-wk Low
$0.63

Latest Key Developments (Source: Significant Developments)

Eleven Biotherapeutics reports Q3 loss per share $0.37
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Eleven Biotherapeutics Inc :Eleven Biotherapeutics reports third quarter 2017 financial results.Q3 loss per share $0.37.Eleven Biotherapeutics Inc - ‍topline 3-month data from phase 3 trial of Vicinium on track for mid-2018​.Eleven Biotherapeutics - did not record any revenue for three months ended September 30, 2017, compared to revenue of $28.7 million for same period in 2016​.Eleven Biotherapeutics - ‍anticipates cash at Sept 30, net $7.0 million raised in Nov will fund research, development programs, operations into mid-2018​.  Full Article

Eleven Biotherapeutics says expects to report no revenue ‍for 3 months ended Sept 30
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Eleven Biotherapeutics Inc -:Eleven Biotherapeutics - ‍for 3 months ended Sept 30, co expects to report no revenue compared to $28.7 million in revenue for 3 months ended Sept 30, 2016​.Eleven Biotherapeutics - ‍intends to make accounting adjustments in financial statements in connection with finalization of accounting of Viventia deal ​.  Full Article

Eleven Biotherapeutics CFO steps down; Richard Fitzgerald named interim CFO
Saturday, 14 Oct 2017 

Oct 13 (Reuters) - Eleven Biotherapeutics Inc -:Eleven Biotherapeutics appoints Richard Fitzgerald as interim chief financial officer.Eleven Biotherapeutics Inc - ‍ John McCabe, who currently holds chief financial officer position, will be stepping down​.  Full Article

Eleven Biotherapeutics ‍appoints Richard Fitzgerald as interim CFO
Saturday, 14 Oct 2017 

Oct 13 (Reuters) - Eleven Biotherapeutics Inc :Eleven Biotherapeutics Inc - ‍appointed Richard F. Fitzgerald, age 54, as company's interim Chief Financial Officer, effective October 13, 2017​.Eleven Biotherapeutics Inc - ‍on October 6, 2017, John J. McCabe resigned as Chief Financial Officer of company, effective as of October 20, 2017​.  Full Article

Clairmark Investments reports 14.8 pct stake in Eleven Biotherapeutics
Thursday, 29 Sep 2016 

Eleven Biotherapeutics Inc :Clairmark Investments reports 14.8 pct stake in Eleven Biotherapeutics as of September 20, 2016.  Full Article

Eleven Biotherapeutics sells $13.5 mln in equity financing - SEC filing
Wednesday, 28 Sep 2016 

Eleven Biotherapeutics Inc: Says sold $13.5 mln in equity financing - SEC filing .Eleven Biotherapeutics Inc discloses in form-D to U.S. SEC that total offering amount was $13.5 mln.  Full Article

Eleven Biotherapeutics to cut a portion of co's workforce
Thursday, 23 Jun 2016 

Eleven Biotherapeutics Inc : Eleven Biotherapeutics Inc says on June 16 board approved a strategic restructuring to eliminate a portion of co's workforce . Board approved a strategic restructuring of the company to eliminate a portion of the company’s workforce . Will eliminate 14 positions across organization, representing approximately 70 percent of company's workforce . The company currently expects to record the restructuring charges during the second and third quarters of 2016 . Currently anticipates incurring total restructuring costs of approximately $0.9 million .Currently expects to record restructuring charges during second and third quarters of 2016.  Full Article

Eleven Biotherapeutics says license agreement with Roche has two "option periods"
Monday, 13 Jun 2016 

Eleven Biotherapeutics Inc : Agreement has 2 'option periods' during which Roche may elect to make one-time payment to company, terminate obligations under agreement . Roche may use buy-out option after first dosing in first phase II study for licensed product until day before initiation of first phase III study . Roche may exercise buy-out option following first dosing and pay company $135 million within 30 days after exercise of option . Roche may exercise buy-out option following day after initiation of first phase III study for licensed product until day before acceptance for review .Roche may exercise buy-out option following day after initiation of first phase iii study and pay co $265 million to terminate obligations.  Full Article

Eleven Biotherapeutics signs license agreement with Roche
Monday, 13 Jun 2016 

Eleven Biotherapeutics Inc : Says Eleven Biotherapeutics has agreed to grant an exclusive, worldwide license to Roche to develop and commercialize EBI-031 . Investigational New Drug (IND) submission for EBI-031 announced Monday [nBw1FHCRwa] . Will be entitled to an upfront payment of $7.5 million, along with potential future milestone payments of up to $262.5 million . First milestone payment will equal $22.5 million if IND becomes effective on or before September 15, 2016 . First milestone payment will equal $20.0 million if IND becomes effective after September 15, 2016 . Under terms of agreement, eleven has agreed to grant exclusive, worldwide license to Roche to develop and commercialize EBI-031 . In addition, eleven could be entitled to receive royalties for net sales of potential future products containing EBI-031 .Eleven Biotherapeutics announces signing of exclusive license agreement.  Full Article

Eleven Biotherapeutics reports Phase 3 Data on Isunakinra (EBI-005) in Allergic Conjunctivitis
Saturday, 16 Jan 2016 

Eleven Biotherapeutics Inc:Announced top-line results from the Phase 3 clinical trial of its lead drug candidate, isunakinra (EBI-005), for the treatment of severe allergic conjunctivitis.Isunakinra was generally well tolerated, with 94% of the patients completing the trial and there were no serious adverse events reported.  Full Article